Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Common Equity (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Common Equity for 9 consecutive years, with $450.1 million as the latest value for Q4 2025.

  • Quarterly Common Equity changed N/A to $450.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $450.1 million through Dec 2025, changed N/A year-over-year, with the annual reading at $450.1 million for FY2025, N/A changed from the prior year.
  • Common Equity for Q4 2025 was $450.1 million at Soleno Therapeutics, down from $494.8 million in the prior quarter.
  • The five-year high for Common Equity was $494.8 million in Q3 2025, with the low at $232.3 million in Q1 2025.